Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis-Reference-Cited by-同舟云学术

Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis

Published:2021-02 Issue:3 Volume:5 Page:356-363
ISSN:2397-9070
Container-title:JGH Open
language:en
Short-container-title:JGH Open

Author:

Loosen Sven H¹²,Schulze‐Hagen Max³,Vucur Mihael¹,Gorgulho Joao²,Paffenholz Pia⁴,Benz Fabian⁵,Mohr Raphael⁵,Demir Münevver⁵,Wree Alexander⁵,Kuhl Christiane³,Trautwein Christian²,Tacke Frank⁵,Bruners Philipp³,Luedde Tom¹,Roderburg Christoph⁵^ORCID

Affiliation:

1. Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf Medical Faculty of Heinrich Heine University Düsseldorf Düsseldorf Germany

2. Department of Medicine III University Hospital RWTH Aachen Aachen Germany

3. Department of Diagnostic and Interventional Radiology University Hospital RWTH Aachen Aachen Germany

4. Department of Urology University Hospital Cologne Cologne Germany

5. Department of Hepatology and Gastroenterology Charité University Medicine Berlin Berlin Germany

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12501

Reference36 articles.

1. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis

2. Cancers Metastatic to the Liver

3. Multidisciplinary approach of colorectal cancer liver metastases

4. Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data

5. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma